Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
MyUPMC experiences major jump in video visits as patients move to online care
More patients than ever are heading for UPMC’s digital front door as the COVID-19 pandemic …
Read More →
Spurred by crisis, telemedicine is revolutionizing health care as we know it
Telemedicine, the remote delivery of health care using video and audio communication tools, is demonstrating …
Read More →